Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

New This Week On Slingshot Insights SA Premium Service: 1/14/2019

|Includes: AbbVie Inc. (ABBV), AGIO, BLUE, IMGN, JAZZ, RHHBY, XENE

This series of instablog posts will highlight the most recently executed transcripts being added to the “Become the Smart Money” , Slingshot Insights Seeking Alpha Premium service. In these blog posts we will give you a bit more information about the subject matter experts we interviewed, the topics covered, and relevant companies. We hope that these brief overviews, combined with our free content and articles, will display what we believe is the content’s unique value to our members. Please don’t hesitate to directly ask us questions at any time via SeekingAlpha Direct message or email to info@slingshotinsights.com.

Why Do Expert Research?

While many individuals we speak to are unaware of the role expert interviews play for many professional investors, it is a $600mm industry. Many funds pay in excess of $100,000 a year just for a relationship with an expert network and over a thousand dollars per call. While these numbers sound staggering, many investors consider them well worth the money. Slingshot Insights’ sharing model has transformed the price of these calls for our customers and now we are making them even more affordable to you on the SeekingAlpha Marketplace for only $75 per month.

Become the newest subscriber to “Become the Smart Money” here and gain access to all of these : Link

Transcript 1: Examining the KCNQ2 seizure landscape with a focus on Ezogabine/retigabine (XEN496), a potassium channel modulator for the treatment of epilepsy

Ticker: XENE

Who's the Expert?

  • Associate Professor of Neurology and Pediatrics at UCSF and pediatric epitologist.
  • Currently manages 750 patients with epilepsy and over 75 patients with Dravet syndrome.
  • Clinical and research interests in OCDH-9 epilepsy and Dravet syndrome; investigator on the ZX008 study.

Interview Goal: To discuss the epilepsy treatment landscape. This call will focus on XEN-496 (Ezogabine/retigabine) which was previously marketed by GlaxoSmithKline in various indications as Potiga, but is now in development by Xenon Pharma.

Link to original project page on Slingshot Insights with questions asked: link

Transcript 2: A third Look: Understanding the potential of IMGN's Mirvetuximab soravtansine (IMGN853) in the ovarian cancer landscape

Ticker: IMGN

Who's the Expert?

  • Gynecologic Oncologist in full-time practice; Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School. Chief Medical Officer of the Massachusetts General Physicians Organization.
  • Currently manages 350 patients with ovarian cancer.
  • PI of clinical trials evaluating novel therapies in the treatment of ovarian cancer, as well as the design of a novel device for delivery of intra-peritoneal catheter.

Interview Goal: To explore the market potential of Immunogen's Mirvetuximab soravtansine (IMGN853), an antibody-drug conjugate currently in development for patients with folate receptor alpha (FRα)-positive cancer.

Link to original project page on Slingshot Insights with questions asked: link

Transcript 3: A Community Oncologist's View: Discussing the current treatment landscape for AML (Vyxeos, Idhifa/Tibsovo) and where Venclexta could fit in after recently gaining FDA accelerated approval

Ticker: JAZZ , OTCQX:RHHBY , ABBV , AGIO

Who's the Expert?

  • Medical oncologist within community practice (NY Oncology Hematology).
  • Currently manages 20 patients with AML, 15 stage 4 RCC and 10 stage 1-3 RCC patients.
  • Board Certified in Internal Medicine and Medical Oncology; fellowship trained (Oncology) at Mount Sinai.

Interview Goal: To speak with an oncologist on the current standard of care in the AML treatment landscape and to understand the market potential of Venclexta and the use of currently approved therapies.

Link to original project page on Slingshot Insights with questions asked: link

Transcript 4: Discussing BLUE’s new SCD results from ASH 2018 and the sickle cell treatment landscape

Ticker: BLUE

Who's the Expert?

  • Professor of Pediatric Hematology-Oncology and Director of Pediatric Sickle Cell.
  • Currently manages 170 patients with sickle cell; Active investigator in multicenter clinical trials of potential therapies for sickle cell sponsored by pharmaceutical companies and by NIH
  • Research experience with mouse models and human studies on vascular adhesion of blood cells and inflammation as contributors to sickle vaso-occlusive pain, partial chimeric stem cell transplant for cure, sickle acute chest syndrome, priapism, and nitric oxide therapy.

Interview Goal:To speak to an expert to better understand BlueBird Bio's new data presented at ASH 2018 on their LentiGlobin gene therapy product. This call will also look to better understand current treatment paradigms and how patients/ physicians choose and will choose therapies.

Link to original project page on Slingshot Insights with questions asked: link

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.